Show simple item record

dc.creatorStojanović, Ivana
dc.creatorDimitrijević, Mirjana
dc.creatorVives-Pi, Marta
dc.creatorMansilla, Maria Jose
dc.creatorPujol-Autonell, Irma
dc.creatorRodríguez-Fernandez, Silvia
dc.creatorPalova-Jelínkova, Lenka
dc.creatorFunda, David P.
dc.creatorGruden-Movsesijan, Alisa
dc.creatorSofronić-Milosavljević, Ljiljana
dc.creatorHilkens, Catharien M. U.
dc.creatorCaceres, Eva Martinez
dc.creatorMiljković, Đorđe
dc.date.accessioned2017-11-23T11:30:53Z
dc.date.available2900-01-01
dc.date.issued2017
dc.identifier.issn1381-6128
dc.identifier.urihttp://www.eurekaselect.com/150098/article
dc.identifier.urihttps://ibiss-r.rcub.bg.ac.rs/handle/123456789/2819
dc.description.abstractCell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
dc.rightsrestrictedAccess
dc.sourceCurrent Pharmaceutical Design
dc.subjectCell-based tolerogenic therapy
dc.subjectMultiple sclerosis
dc.subjectRegulatory T cells
dc.subjectRheumatoid arthritis
dc.subjectTolerogenic dendritic cells
dc.subjectType 1 diabetes
dc.titleCell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis
dc.typearticle
dc.rights.licenseARR
dcterms.abstractРодрíгуез-Фернандез, Силвиа; Фунда, Давид П.; Палова-Јелíнкова, Ленка; Пујол-Aутонелл, Ирма; Миљковић, Ђорђе; Вивес-Пи, Марта; Стојановић, Ивана; Цацерес, Ева Мартинез; Хилкенс, Цатхариен М. У.; Груден-Мовсесијан, Aлиса; Мансилла, Мариа Јосе; Димитријевић, Мирјана; Софронић-Милосављевић, Љиљана;
dc.rights.holder© 2017 Bentham Science Publishers
dc.citation.issue18
dc.citation.volume23
dc.description.otherCurrent Pharmaceutical Design (2017), 23(18): 2623-2643
dc.identifier.doi10.2174/1381612823666170214120708
dc.identifier.pmid28201972
dc.identifier.scopus2-s2.0-85025164921
dc.identifier.wos000405678800007
dc.citation.apaStojanovic, I., Dimitrijevic, M., Vives-Pi, M., Mansilla, M. J., Pujol-Autonell, I., Rodríguez-Fernandez, S., Palova-Jelínkova, L., et al. (2017). Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis. Current Pharmaceutical Design, 23(18), 2623–2643.
dc.citation.vancouverStojanovic I, Dimitrijevic M, Vives-Pi M, Mansilla MJ, Pujol-Autonell I, Rodríguez-Fernandez S, Palova-Jelínkova L, Funda DP, Gruden-Movsesijan A, Sofronic-Milosavljevic L, Hilkens CMU, Caceres EM, Miljkovic D. Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis. Curr Pharm Des. 2017;23(18):2623–43
dc.citation.spage2623
dc.citation.epage2643
dc.type.versionpublishedVersionen
dc.citation.rankM21


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record